Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
1 clinical trials · Condition
◉ Watch Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (NCT01997333) | Celldex Therapeutics | 2013-11-01 |
Track Metastatic gpNMB Over-expressing Triple Negative Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.